Canagliflozin filed by Janssen Cilag in EU for Type 2 Diabetes

Janssen-Cilag has submitted an EU filing for canagliflozin, an oral, once-daily sodium glucose co-transporter 2 (SGLT2) inhibitor, for the treatment of adult patients with Type 2 Diabetes. Janssen R&D filed canagliflozin in the USA at the end of May 2012. Data from the first two head-to-head pivotal trials of canagliflozin showed that it has improved efficacy over established antidiabetics, without any sign yet of the cancer and liver signals that delayed dapagliflozin.Janssen has rights to canagliflozin through a licence agreement with Mitsubishi Tanabe Pharma in North America, South America, Europe, Middle East, Africa, Australia, New Zealand and parts of Asia.